Alder Biopharmaceuticals Inc (NASDAQ:ALDR) was the recipient of some unusual options trading on Monday. Stock traders acquired 1,113 put options on the stock. This represents an increase of 1,924% compared to the average daily volume of 55 put options.

ALDR has been the subject of several recent research reports. Mizuho restated a “buy” rating and issued a $29.00 price objective on shares of Alder Biopharmaceuticals in a report on Wednesday, January 31st. Canaccord Genuity set a $22.00 price objective on Alder Biopharmaceuticals and gave the company a “buy” rating in a report on Friday, January 12th. BMO Capital Markets restated a “buy” rating and issued a $22.00 price objective on shares of Alder Biopharmaceuticals in a report on Wednesday, January 3rd. BidaskClub upgraded Alder Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, January 4th. Finally, Zacks Investment Research downgraded Alder Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, January 11th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $27.93.

Alder Biopharmaceuticals (NASDAQ ALDR) traded up $1.05 on Wednesday, reaching $14.35. The company’s stock had a trading volume of 2,481,426 shares, compared to its average volume of 2,080,000. Alder Biopharmaceuticals has a 52 week low of $8.60 and a 52 week high of $24.65. The stock has a market capitalization of $971.69, a price-to-earnings ratio of -2.67 and a beta of 2.60.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in Alder Biopharmaceuticals by 5.5% in the second quarter. Vanguard Group Inc. now owns 3,626,573 shares of the biopharmaceutical company’s stock valued at $41,525,000 after purchasing an additional 187,871 shares during the last quarter. Janus Henderson Group PLC purchased a new position in Alder Biopharmaceuticals in the second quarter valued at about $36,956,000. State Street Corp grew its stake in Alder Biopharmaceuticals by 9.4% in the second quarter. State Street Corp now owns 1,944,755 shares of the biopharmaceutical company’s stock valued at $22,267,000 after purchasing an additional 167,642 shares during the last quarter. Emerald Advisers Inc. PA grew its stake in Alder Biopharmaceuticals by 9.6% in the fourth quarter. Emerald Advisers Inc. PA now owns 1,730,028 shares of the biopharmaceutical company’s stock valued at $19,809,000 after purchasing an additional 151,551 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in Alder Biopharmaceuticals by 9.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,661,997 shares of the biopharmaceutical company’s stock valued at $19,030,000 after purchasing an additional 145,503 shares during the last quarter. Institutional investors own 97.22% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://theolympiareport.com/2018/02/14/stock-traders-buy-high-volume-of-put-options-on-alder-biopharmaceuticals-aldr.html.

Alder Biopharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.